The FDA has accepted for review a supplemental biologics license application for the use of Menactra for active immunization of infants and toddlers for the prevention of invasive meningococcal disease.
The FDA has accepted for review a supplemental biologics license application for the use of Menactra for active immunization of infants and toddlers for the prevention of invasive meningococcal disease.
Menactra is designed to help offer protection against 4 serogroups of N meningitidis, the bacterium that causes meningococcal infection. Meningococcal disease can be difficult to recognize because symptions are similar to those of more common viral illnesses. However, the disease can progress quickly and can cause death within 24 hours.
Results from clinical studies show that a dose of the vaccine at 9 and 12 months of age elicits a robust immune response against the 4 serogroups. Reactions were similar to those for other infant vaccines, including swelling and tenderness at the site of vaccination and irritability. Most of these side effects were mild and of short duration.
Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
December 4th 2023In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.